Coming back to post #6, because the follow-up matters more than the original answer.
Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
post #40 is right about the mechanism and I think understates the practical bit.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
Coming back to post #60, because the follow-up matters more than the original answer.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
Read the full topic (100 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 54k | 19mo | |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
|
+127 | 150 | 41k | 20mo |
|
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…
|
+22 | 29 | 356 | 11mo |
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+12 | 16 | 2.8k | 11mo |
|
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
|
+70 | 74 | 7k | 8mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
|
+124 | 132 | 9.2k | 2mo |
|
Peer-to-peer review: what actually happens on the call
On the subject in the title: Peer-to-peer review: what actually happens on the call Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires.…
|
2 | 1.2k | 1d | |
|
Enforcement priorities versus written rules
Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…
|
2 | 62k | 15mo | |
|
Pharmacy supply in the UK and the questions you will be asked
On the subject in the title: Pharmacy supply in the UK and the questions you will be asked Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+95 | 105 | 1.3k | 4mo |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
+87 | 94 | 1.1k | 21d |